Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2017 | 12-2016 | 09-2016 | 06-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,890,718 | 5,144,327 | 6,067,611 | 5,409,531 | 4,599,807 |
| Marketable Securities | 521,811 | 1,649,385 | 1,176,314 | 1,405,239 | 816,376 |
| Receivables | 4,240,467 | 4,571,148 | 4,372,750 | 4,095,887 | 4,048,619 |
| Inventories | 2,112,111 | 2,050,772 | 2,331,646 | 2,252,469 | 2,203,676 |
| Other current assets | 672,253 | 1,821,958 | 597,839 | 540,684 | 1,039,162 |
| TOTAL | $11,437,360 | $15,237,590 | $14,546,160 | $13,703,810 | $12,707,640 |
| Non-Current Assets | |||||
| PPE Net | 4,791,033 | 4,814,489 | 5,267,363 | 4,922,853 | 4,237,087 |
| Investments And Advances | 2,767,473 | 3,016,984 | 3,010,021 | 2,756,111 | 2,425,839 |
| Intangibles | 18,978,615 | 13,452,286 | 12,796,821 | 12,728,659 | 13,260,023 |
| Other Non-Current Assets | 1,138,829 | 1,585,331 | 1,637,455 | 1,386,777 | 1,726,421 |
| TOTAL | $27,675,950 | $22,869,090 | $22,711,660 | $21,794,400 | $21,649,370 |
| Total Assets | $39,113,300 | $38,106,700 | $37,257,800 | $35,498,210 | $34,357,010 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,832,715 | 2,169,765 | 2,072,377 | 1,996,012 | 819,975 |
| Accounts payable and accrued liabilities | 1,976,697 | 2,132,854 | 1,929,395 | 1,769,883 | 1,397,444 |
| Other current liabilities | 3,856,068 | 3,791,283 | 3,322,582 | 3,308,782 | 5,590,030 |
| TOTAL | $8,456,616 | $8,813,122 | $7,926,603 | $7,651,677 | $8,292,233 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,470,908 | 6,808,506 | 7,250,021 | 6,879,945 | 5,166,992 |
| Other Non-Current Liabilities | 2,444,620 | 2,618,173 | 2,606,601 | 2,532,220 | 2,106,826 |
| TOTAL | $12,325,630 | $10,485,010 | $10,916,580 | $10,462,210 | $8,333,332 |
| Total Liabilities | $20,782,250 | $19,298,120 | $18,843,190 | $18,113,880 | $16,625,570 |
| Shareholders' Equity | |||||
| Common Shares | 591,426 | 597,890 | 636,559 | 603,105 | 529,622 |
| Retained earnings | 14,276,950 | 14,232,350 | 15,421,560 | 14,414,790 | 12,968,830 |
| Other shareholders' equity | 3,353,173 | 3,786,164 | 2,189,602 | 2,233,545 | 3,996,751 |
| TOTAL | $18,331,050 | $18,808,570 | $18,414,620 | $17,384,330 | $17,731,440 |
| Total Liabilities And Equity | $39,113,300 | $38,106,690 | $37,257,810 | $35,498,210 | $34,357,010 |